Rheumatoid arthritis patients often don't notice disease flares until symptoms have already worsened substantially. As joint ...

Both upadacitinib (Rinvoq) and adalimumab (Humira) are proven effective in rheumatoid arthritis (RA) and psoriatic arthritis ...

SaveHealth reports on common rheumatoid arthritis medications, highlighting their effectiveness, side effects, and cost ...

A phase 3 rheumatoid arthritis trial of Lynk Pharmaceuticals’ JAK1 inhibitor in China has hit its primary endpoint, boosting ...

Nearly 1.5 million Americans and nearly 5% of women over the age of 55 have rheumatoid arthritis (RA), an incurable ...

Discover effective strategies to manage arthritis pain during winter, including diet, exercise, and warmth for improved ...

Augurex CEO Neil Klompas describes why it is difficult for biomarkers to diagnose rheumatoid arthritis in some cases.

Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical stage innovative drug development company focused on developing innovative therapies for immune and ...

Lynk Pharmaceuticals shares encouraging topline data from Phase III trials of Zemprocitinib, showing promise in treating rheumatoid arthritis patients effectively.

Women are disproportionately affected by almost every major form of arthritis, and the gap isn’t small. The pattern shows up ...

Drug distributor Cardinal Health raised its 2026 profit forecast on Tuesday, driven ​by robust demand for specialty medicines ...